Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Lu Simon Dazhong filed an amended initial ownership report to correct previously reported equity holdings. The amendment clarifies that he holds options over 17,965 Ordinary Shares at an exercise price of $8.1400 expiring on November 26, 2035, 27,965 restricted share units tied to Ordinary Shares, and 41,457 Ordinary Shares directly. Footnotes state that the number of Ordinary Shares and certain option figures and vesting terms were inadvertently misstated or omitted in the original filing, and provide detailed vesting schedules for both the options and RSUs.
Ascentage Pharma Group International director David Sidransky filed an amended Form 3 to correct his reported equity holdings. The filing now shows stock options over 18,850 Ordinary Shares at an exercise price of 8.1400 expiring on November 26, 2035, vesting in twelve equal monthly tranches starting November 26, 2025. It also reflects 28,850 restricted share units that vest in four equal annual increments on November 26 of 2026, 2027, 2028 and 2029, plus 10,641 directly held Ordinary Shares. Footnotes state that prior submissions inadvertently misstated the number of Ordinary Shares and option details.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Wang Shaomeng filed an initial ownership report showing a mix of direct and indirect stakes in the company’s Ordinary Shares, along with equity awards in the form of options and restricted share units.
Direct holdings include 1,193,032 Ordinary Shares, options over 17,965 Ordinary Shares at an exercise price of $8.14 per share expiring on November 26, 2035, and 27,965 restricted share units, each convertible into one Ordinary Share and scheduled to vest annually on November 26 of 2026, 2027, 2028 and 2029. Additional Ordinary Shares are held indirectly through trusts, with 2,836,845 shares held by KEW Trust and 6,024,066 shares held by Shaomeng Wang Dynasty Trust.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Marc E. Lippman filed an amended Form 3 updating his equity holdings. He now reports stock options covering 17,965 Ordinary Shares at an exercise price of 8.1400 per share expiring on November 26, 2035, 27,965 underlying Ordinary Shares from restricted share units, and 21,174 Ordinary Shares held directly.
The footnotes explain that the options vest in twelve equal monthly tranches starting on November 26, 2025, while the restricted stock units vest in four equal annual increments on November 26 of 2026 through 2029. The filing also states that the number of share options and/or vesting were inadvertently reported incorrectly in the original submission and are corrected here.
ASCENTAGE PHARMA GROUP INTERNATIONAL executive Thomas J. Knapp, SVP and General Counsel, reported his initial ownership in a Form 3. He directly holds options over 38,938 Ordinary Shares with a USD-equivalent exercise price of 8.1400 per share, vesting in four equal installments on 11/26/2026, 2027, 2028 and 2029 and expiring on 11/26/2035. He also holds 38,938 restricted stock units, each representing one Ordinary Share and vesting on the same four dates, and 362,444 Ordinary Shares owned directly.
ASCENTAGE PHARMA GROUP INTERNATIONAL filed an amended Form 3 to update the initial ownership report for Chairman and CEO Yang Dajun. The filing lists existing holdings rather than new trades, covering ordinary shares, stock options and restricted stock units tied to the company’s ordinary shares.
Yang holds ordinary shares directly and also has indirect holdings through the Dajun Yang Dynasty Trust, his spouse, and HealthQuest Pharma Limited, an entity controlled by his spouse, as described in the footnotes. The report also shows options over 143,463 ordinary shares held directly and 103,364 held indirectly, with an exercise price of $8.14 and expiration on November 26, 2035.
The filing further discloses restricted stock units representing 143,463 ordinary shares directly and 103,364 indirectly. Each RSU converts into one ordinary share and vests in four equal installments on November 26 of 2026, 2027, 2028 and 2029, with no expiration date. Footnotes emphasize that many indirect positions are held by the trust or spouse and that Yang disclaims beneficial ownership beyond his economic interest.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Marina Bozilenko filed an amended Form 3 to update her equity awards. She reports stock options over 17,965 Ordinary Shares at an exercise price of 8.1400 per share, expiring on November 26, 2035, vesting in twelve equal monthly tranches starting November 26, 2025.
She also holds restricted share units covering 27,965 Ordinary Shares, which vest in four equal increments on each of November 26, 2026, 2027, 2028 and 2029. The amendment notes that the number and/or vesting of the share options were inadvertently incorrectly reported in the original submission and are now corrected.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Ye Changqing filed an initial ownership report showing equity awards in the company. The filing lists stock options tied to 56,550 Ordinary Shares with an exercise price of $8.1400 per share, expiring on November 26, 2035. These options vest in four equal parts on each of November 26, 2026, 2027, 2028 and 2029.
The filing also reports 66,550 restricted stock units, each representing one Ordinary Share. These RSUs vest in four equal annual installments on the same dates, from November 26, 2026 through 2029, and have no expiration date.
Ascentage Pharma Group International director Marina Bozilenko has filed an initial ownership report showing equity-based compensation holdings. She holds stock options over 53,895 Ordinary Shares with an exercise price of $8.14 per share, expiring on November 26, 2035. These options vest in four equal installments on each of November 26, 2026, 2027, 2028 and 2029.
She also holds restricted stock units representing 63,895 Ordinary Shares. Each RSU converts into one Ordinary Share upon vesting, with the RSUs vesting in four equal installments on the same dates from 2026 through 2029 and having no expiration date. This filing records existing awards and does not show any buy or sell transactions.
ASCENTAGE PHARMA GROUP INTERNATIONAL Chairman and CEO Yang Dajun filed an initial Form 3 showing his equity interests in the company. The filing reports direct ownership of 1,097,994 Ordinary Shares, along with direct holdings of options and restricted stock units tied to additional Ordinary Shares.
The derivative positions include options over 143,463 Ordinary Shares and restricted stock units over another 143,463 Ordinary Shares, vesting in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. The options have an exercise price of $8.14 per share, shown in USD based on the grant-date conversion from HKD.
Entities associated with Yang, including the Dajun Yang Dynasty Trust, his spouse, and an entity controlled by his spouse, hold 22,054,131, 312,534 and 14,089,111 Ordinary Shares, respectively. The filing states that Yang disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.